Mycophenolic acid trough level assessment in patients with lupus nephritis; does it make a difference?

ABSTRACT:

Introduction

Mycophenolate Mofetil (MMF) has become one of the cornerstone treatments of lupus nephritis (LN). It is converted into mycophenolic acid (MPA), an active metabolite, that displays high inter- and intra-individual pharmacokinetic variability. However, the routine monitoring of MPA trough level is still debatable.

Objectives

The present study aims to evaluate the relationship between MPA trough levels and both clinical outcomes and drug-related adverse effects during the maintenance phase of LN in Egyptian patients.

Methods

We included thirty-five adults and twenty-nine children with biopsy-proven class III and IV LN, who had been maintained on steroid and MMF as maintenance therapy for more than six months. Clinical and laboratory markers of lupus activity

SUBMITTER: Abdulgalil AE 

PROVIDER: S-EPMC11905544 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature